Influenza (quadrivalent) vaccine is under clinical development by Vaxxas and currently in Phase I for Influenzavirus A Infections. According to GlobalData, Phase I drugs for Influenzavirus A Infections have a 69% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Influenza (quadrivalent) vaccine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Influenza (quadrivalent) vaccine overview

The vaccine candidate is under development for the prevention of influenzavirus A infections, influenzavirus B infections and seasonal influenza. It is a quadrivalent inactivated influenza virus vaccine administered through intradermal route in the form of patch. The therapeutic candidate is being developed based on high density micro array patch (HD-MAP) technology.

Vaxxas overview

Vaxxas is a biotechnology company that develops and commercializes novel technologies for enhancing the performance of existing and next-generation vaccines. It develops a microneedle array patch based on its proprietary High Density Microarray Patch (HD-MAP) technology, that creates a potent immune response by applying a patch to the skin for few seconds. Vaxxas is targeting applications in infectious diseases and oncology. The company has established partnerships with prominent global entities in vaccine distribution, such as Merck/MSD, the Biomedical Advanced Research and Development Authority (BARDA), the World Health Organization (WHO), and the Bill and Melinda Gates Foundation. The company has operations in the US and Australia. Vaxxas is headquartered in Hamilton, Queensland, Australia.

For a complete picture of Influenza (quadrivalent) vaccine’s drug-specific PTSR and LoA scores, buy the report here.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.